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were mucositis (G3, 5 pts; G4, 1 pt), asthenia (G3, 2 pts), hand-foot syndrome 
(G3, 2 pts). G3/4 neutropenia occurred in only 5 pts (14%) (G3, 4 pts; G4, 1 pt). 
8 pts required dose reductions. Enzymatic analysis in 12 pts to date suggests 
ratios of TP tumor/normal-tissue; TP/DPD in tumor and nuclear TS may be use- 
ful markers of response. Final data will be presented at the meeting. In sum- 
mary, the combination of capecitabine and weekly docetaxel is well tolerated. 
PFS appears similar to every 3 weeks docetaxel, although RR appears higher 
and encourages evaluation of this regimen as a 1st line regimen in NSCLC. 
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Background: Platinum-based chemotherapy remains the standard of care in 
treatment of advanced NSCLC although CDDP-related toxicity is a constant 
concern. A conventional means of minimizing CDDP side effects is to split the 
dose, which is not expected to alter efficacy. 
Patients and Methods: From February 2000 to April 2002, fifty patients with 
advanced NSCLC were treated with CDDP 30 mg/ms and VNR 30 mg/ms IV 
on days 1 and 8 of a three-week cycle for up to 8 cycles. Ondansetron and 
Dexamethasone were prescribed routinely. HRQL was assessed at baseline, 
prior to each cycle, and in initial follow-up using the EORTC core questionnaire, 
QLQ-C30, and lung cancer module, QLQLC13. 
Results: Patient characteristics were average age 63 years (median 64, 
range 37-79) male 23 (46%) ECOG O-l 31 (62%) stage IV or recurrent dis- 
ease 39 (78%), adenocarcinoma 21 (42%). The median number of cycles com- 
pleted was 4 (range l-6). Median survival was 256 days, with one-year survival 
38%. CTC version 2 grade 3/4 toxicities included neutropenia 23 (46%), ane- 
mia 7 (14%) and thrombocytopenia 1 (2%). Four patients (8%) had febrile neu- 
tropenic episodes, 11 (22%) received blood transfusions, and 1 (2%) received 
platelet transfusion. There was no grade 3/4 renal dysfunction although grade 
l/2 elevations in serum creatinine occurred in 11 patients (22%) necessitating 
dose modifications and/or delays. Compliance with HRQL assessments at each 
time point ranged from 78-l 00%. Rated as ‘quite a bit’ or ‘very much’ were nau- 
sea in 18/44 (41%) vomiting in 8/44 (18%) and tingling in the hands or feet in 
8/44 (18%). By the end of the last cycle, 21/39 patients (54%) demonstrated a 
clinically significant greater than 1 O-point decline in global health status score 
compared to baseline, while 14/39 (36%) had stable or improved scores. Fur- 
ther analyses of HRQL outcomes will be presented. 
Conclusions: Survival and toxicity with this schedule of CDDP and VNR are 
comparable to other established platinum-based regimens used in treatment of 
NSCLC. HRQL is also similar to results from recent randomized trials. Estab- 
lishing that split-dose CDDP is associated with less CDDP-related toxicity and 
improves HRQL requires further study. 
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Background: Brain metastases are frequent in NSCLC, either at diagnosis or 
during follow-up. Patients with inoperable metastasis are treated with whole 
brain radiotherapy (WBR) and have a poor prognosis, with median survival 
shorter than 6 months. Despite the availability of platinum-based chemother- 
apy, patients with brain metastases are often excluded from clinical trials, be- 
cause it is considered that the blood-brain-barrier does not allow chemotherapy 
drugs to enter in the central nervous system (CNS). Yet, this has been refuted 
by some investigators. Therefore, the purpose of this study was to evaluate the 
efficacy of gemcitabine and cisplatin in the treatment of NSCLC patients with 
unresectable brain metastases. 
Patients and methods: Patients with NSCLC and unresectable CNS metas- 
tasis were enrolled in this phase II study. All patients signed informed consent. 
Treatment consisted of gemcitabine 1000 mg/m* and cisplatin 50 mg/ms, both 
delivered on days 1 and 8, every three to four weeks. 
Results: 26 consecutive patients were enrolled in our institution. 22 had syn- 
chronous brain metastases and were chemotherapy-naive. 4 patients were en- 
rolled after brain relapse following previous chemotherapy (disease free inter- 
val: mean: 13.2 months, range: 9-26). Two patients were not evaluable because 
of early death, after 6 and 8 weeks, repectively. After 2 cycles, the documented 
CT scan response rate (RR) in brain metastases was 71% in 24 evaluable pa- 
tients After 4 cycles the RR was 73% in 15 evaluable patients. With 7 complete 
responses and 8 partial responses, the overall RR was 62%. One patient had 
stable disease. All but three of the responding patients had a response on their 
primary lung tumor lesion. The mean duration of response was 6.8 months and 
the overall mean survival is 5.4 months overall and 7,2 months in responding 
patients. Toxicity: no infection, no bleeding, no non-hemato toxicity P gr2 was 
seen; no particular CNS toxicity post radiotherapy was noticed (42% of the pa- 
tients received WBR). 
Conclusions: This chemotherapy regimen shows encouraging activity in 
NSCLC patients with CNS metastases. Further trials in patients with NSCLC 
and CNS metastases are warranted. 
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Brain recurrences from non-small cell lung cancer (NSCLC) are generally asso- 
ciated with poor-prognosis; the median survival (MS) after presentation do not 
exceed 3 to 4 months. Whole-brain radiotherapy (WBRT) represent the gold- 
standard treatment in this setting; it may induce only a modest improve in MS 
and do not represent a real chance of cure. There’s actually no one standard 
therapeutic approach for those patients (PTS) who experience progressive dis- 
ease after WBRT. Oral Temozolomide (TMZ) is a second-generation alkylating 
agent that showed efficacy against cerebral recurrences from various type of 
solid turnours. From 1 O/2000 we started a phase II study to assess the efficacy 
and the tolerability of TMZ, given orally at the dose of 200 mg/mq for 5 con- 
secutive days in a 28-days cycle, in PTS affected by cerebral metastases from 
NSCLC that progressed after WBRT.PTS pretreated with almost one line of 
chemotherapy (CHT) for the primary tumour and/or extra-cerebral recurrences, 
with evaluable disease assessed by CT and/or MRI, ECOG-PS 0 - 3, and ad- 
equate hematological, hepatic and renal functions were considered eligible. 
Thirteen PTS entered onto the study; the median age was 65 years and the 
median ECOG-PS was 1. TMZ shown high tolerability in this subset of PTS, 
with no grade 3 or 4 toxicity registered. We performed a first analysis on may 
2002; the overall response rate (ORR) was 61%, with two PTS that achieved 
a complete response (CR), and six stable disease, with a median survival of 7 
months for the entire group. Among the responders PTS, the median duration 
of response (MDR) was 11 months. We recently updated our series; three PTS 
were still alive at 13, 16 and 22 months from the start of the therapy, respectively. 
Two of them have been experienced an extra-cerebral progression of the dis- 
ease so they underwent salvage CHT based on docetaxel combined with TMZ; 
their brain metastases remain stable 2 and 6 months later the progression out- 
side the central nervous system, respectively. Among the ten deceased PTS, 
we observed 8 progressive-disease-related deaths (80%) and 2 (20%) tumour- 
unrelated deaths in PTS who experienced post-radiotherapy-cerebral necrosis. 
Oral TMZ, alone or combined with other agents, is safe and well tolerated in 
this setting and may represent a valid therapeutic option in this poor-prognosis 
subset of PTS. It also seems able to induce long-term remissions in a small 
subgroup of PTS. 
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XPD takes part in the unwinding of DNA and forms a complex with the basal 
transcription factor TFIIH during transcription-coupled repair. Two functional 
polymorphisms in XPD (Lys75lGln and Asp312Asn) have been related to lung 
